| Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group I Puzanov, A Diab, K Abdallah, CO Bingham, C Brogdon, R Dadu, ... Journal for immunotherapy of cancer 5, 1-28, 2017 | 1693 | 2017 |
| Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients FS Hodi, MC Mihm, RJ Soiffer, FG Haluska, M Butler, MV Seiden, T Davis, ... Proceedings of the National Academy of sciences 100 (8), 4712-4717, 2003 | 1202 | 2003 |
| Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy H Rehman, AW Silk, MP Kane, HL Kaufman Journal for immunotherapy of cancer 4, 1-8, 2016 | 368 | 2016 |
| Ipilimumab and radiation therapy for melanoma brain metastases AW Silk, MF Bassetti, BT West, CI Tsien, CD Lao Cancer medicine 2 (6), 899-906, 2013 | 309 | 2013 |
| Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the … I Puzanov, A Diab, K Abdallah, CO Bingham 3rd, C Brogdon, R Dadu, ... J immunother Cancer 5 (1), 95, 2017 | 223 | 2017 |
| Immune activation and benefit from avelumab in EBV-positive gastric cancer A Panda, JM Mehnert, KM Hirshfield, G Riedlinger, S Damare, ... JNCI: Journal of the National Cancer Institute 110 (3), 316-320, 2018 | 184 | 2018 |
| Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors K Margolin, C Morishima, V Velcheti, JS Miller, SM Lee, AW Silk, ... Clinical Cancer Research 24 (22), 5552-5561, 2018 | 169 | 2018 |
| Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer JH Newman, CB Chesson, NL Herzog, PK Bommareddy, SM Aspromonte, ... Proceedings of the National Academy of Sciences 117 (2), 1119-1128, 2020 | 154 | 2020 |
| Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition EI Buchbinder, JP Dutcher, GA Daniels, BD Curti, SP Patel, SG Holtan, ... Journal for immunotherapy of cancer 7, 1-7, 2019 | 153 | 2019 |
| Oncolytic viruses—natural and genetically engineered cancer immunotherapies SR Jhawar, A Thandoni, PK Bommareddy, S Hassan, FJ Kohlhapp, ... Frontiers in Oncology 7, 202, 2017 | 145 | 2017 |
| First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors MN Stein, JR Bertino, HL Kaufman, T Mayer, R Moss, A Silk, N Chan, ... Clinical cancer research 23 (15), 4163-4169, 2017 | 143 | 2017 |
| Biomarkers for immunotherapy: current developments and challenges KR Spencer, J Wang, AW Silk, S Ganesan, HL Kaufman, JM Mehnert American Society of Clinical Oncology Educational Book 36, e493-e503, 2016 | 128 | 2016 |
| Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers M Palmeri, J Mehnert, AW Silk, SK Jabbour, S Ganesan, P Popli, ... ESMO open 7 (1), 100336, 2022 | 124 | 2022 |
| Clinical management of multiple melanoma brain metastases: a systematic review S Goyal, AW Silk, S Tian, J Mehnert, S Danish, S Ranjan, HL Kaufman JAMA oncology 1 (5), 668-676, 2015 | 97 | 2015 |
| Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors A Panda, A Betigeri, K Subramanian, JS Ross, DC Pavlick, S Ali, ... JCO precision oncology 1, 1-13, 2017 | 70 | 2017 |
| Reexamining the physical examination for obese patients AW Silk, KM McTigue Jama 305 (2), 193-194, 2011 | 59 | 2011 |
| Immunologic characteristics of nonmelanoma skin cancers: implications for immunotherapy. ET Hall, E Fernandez-Lopez, AW Silk, R Dummer, S Bhatia American Society of Clinical Oncology educational book. American Society of …, 2020 | 58 | 2020 |
| Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration MN Stein, J Malhotra, RS Tarapore, U Malhotra, AW Silk, N Chan, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 56 | 2019 |
| Intratumoral approaches for the treatment of melanoma PK Bommareddy, AW Silk, HL Kaufman The Cancer Journal 23 (1), 40-47, 2017 | 54 | 2017 |
| Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015 PA Ascierto, S Agarwala, G Botti, A Cesano, G Ciliberto, MA Davies, ... Journal of translational medicine 14, 1-25, 2016 | 51 | 2016 |
